ENChemotherapy in Germany is not a drip chosen by the disease name but a regimen of named drugs, doses and intervals, set once the tumour type and tissue analysis are known. Its drugs, cytostatics, stop tumour cells dividing.
Below: who decides, where treatment happens, who receives chemotherapy and when it is postponed, how a course runs and its forms, side effects and what to settle before travelling. Individual cancers have their own pages; the overview is cancer treatment in Germany.
Who decides the regimen and where chemotherapy is given
In a certified German cancer centre a tumour board, not one doctor, signs off the regimen: usually an oncologist, surgeon, radiologist, pathologist and radiation oncologist. Patients are entitled to know the decision: by law the doctor must explain the treatment and equivalent alternatives.
The decision rests on tumour type and subtype, stage, microscopic and genetic tissue tests, general condition and other illnesses, so one diagnosis can mean different regimens: tumours sharing a name differ. Doses follow height and weight and are lowered, or the drug changed, if the kidneys work poorly.
A regimen from abroad is sometimes revised: key tissue tests are missing, the choice departs from German guidelines, or doses need recalculating. An oncologist then reviews reports, scans and slides: a second opinion from a German doctor. The Krebsinformationsdienst explains how chemotherapy is chosen.
Certified centres give chemotherapy: the German Cancer Society (DKG) certifies organ centres, such as breast or bowel, and oncology centres; Deutsche Krebshilfe awards the top status, Comprehensive Cancer Center. Drugs are given in a day unit or specialist practice under a haematologist-oncologist or, for some tumours, a gynaecological oncologist, urologist or gastroenterologist qualified in drug treatment of tumours (Medikamentöse Tumortherapie). Examples: at München Klinik Harlaching the haematology, oncology and palliative medicine department, chief physician Prof. Stefan Böck, treats solid tumours and blood cancers; at Tübingen University Hospital, Prof. Lars Zender’s medical oncology and pulmonology department runs early trials of new drugs; Krankenhaus Nordwest in Frankfurt belongs to the UCT Frankfurt–Marburg, certified by Deutsche Krebshilfe; Dr Daniela Grenacher-Horn’s practice Münchner Onkologie has its own chemotherapy day unit. More: cancer hospitals in Germany.
Who receives chemotherapy and when it is postponed
Chemotherapy is given when the tumour type responds to the drugs and the tumour board sees a benefit for this patient. It is the backbone of treatment in leukaemias, lymphomas, testicular and many childhood tumours, part of combined treatment in breast, bowel, stomach, pancreatic, lung and ovarian cancer, and minor elsewhere. Breast and lung cancer, lymphoma and leukaemia regimens have their own pages.
It is postponed when risk outweighs benefit: blood counts have not recovered, there is an active infection or unhealed surgical wound, the liver, kidneys or heart are badly impaired, or general condition is very weak; in early pregnancy especially, the drugs can harm the baby. So blood tests and an examination precede every cycle, and postponing one is a safety step, not the end of treatment.
How a course runs and the forms chemotherapy takes
Chemotherapy runs in cycles: one or more days of drugs, then a break while blood counts recover; many courses last several months. Intervals are not moved without reason, since needless delays and dose cuts can weaken treatment.
Most chemotherapy is given in a day unit: a session lasts from half an hour to several hours, then the patient returns to the hotel. A hospital stay is needed if treatment is poorly tolerated or for very intensive regimens, as in some leukaemias and lymphomas.
Drugs go into an arm vein or a port, a small chamber with a tube placed under the skin, usually below the collarbone. For longer treatment a port spares the veins, avoids repeated needles and lowers the risk of leaks into tissue; staff look after it. Before the first cycle come blood tests and, for some regimens, heart, hearing or lung checks.
Some drugs, such as capecitabine, are tablets taken at home. Regional chemotherapy brings the drug straight to the tumour: in peritoneal carcinomatosis a heated drug solution rinses the abdomen during surgery (HIPEC), its benefit still debated for some tumours; in liver tumours the drug enters the feeding artery and the tumour’s vessels are blocked (chemoembolisation); in some leukaemias and brain involvement it enters the spinal fluid. High-dose chemotherapy destroys blood formation, so the patient’s own stem cells are frozen first and returned afterwards.
Side effects: why they occur and what is done about them
Side effects occur because the drugs hit all rapidly dividing cells, including hair roots, mucous membranes and bone marrow, so most pass after treatment. In Germany supportive care is planned with the regimen, not after the patient feels ill: anti-sickness drugs matched to the regimen’s nausea risk precede the infusion, marrow-stimulating injections follow cycles with a high white-cell risk, and dental and vaccination checks come first. See the German S3 guideline on supportive therapy.
Nausea, fatigue, hair loss, taste changes and numb hands and feet are typical. Hair usually regrows, fatigue can last longer and numbness sometimes persists, so report it at once. Serious complications are possible, above all infection when white cells are low: a temperature above 38 degrees, chills or bleeding mean calling the unit immediately. Anti-sickness drugs prevent nausea and vomiting in seven or eight patients in ten, but nobody can promise no side effects.
A daily diary helps: temperature, nausea, bowels, sleep, numbness and other medicines or supplements. Shown at every visit, it lets the doctor adjust doses or supportive drugs and spot interactions. Late effects of some drugs on nerves, heart, kidneys, lungs or fertility are discussed beforehand and checked afterwards, and fertility preservation comes before the first cycle. On regaining strength: rehabilitation after cancer treatment.
What chemotherapy aims at and how it is combined with other treatments
The aim is named before treatment starts. Sometimes it is cure, as in some blood cancers and testicular tumours. Before surgery chemotherapy shrinks the tumour, sparing healthy tissue or making surgery possible, and shows whether the drugs work; after surgery it destroys remaining tumour cells and lowers the risk of relapse. When cure is impossible, it holds the disease back and relieves symptoms.
Chemotherapy acts on all rapidly dividing cells, targeted therapy on a specific tumour feature that not every tumour has, and immunotherapy releases the immune system’s brakes or directs it at the tumour; see cancer immunotherapy in Germany. They are often combined: trastuzumab with chemotherapy in HER2-positive breast cancer, pembrolizumab with platinum-based chemotherapy in a form of lung cancer.
What the cost is made of
The bill covers the drugs and their preparation in the hospital pharmacy, day-unit days, tests before every cycle and supportive medication. These recur each cycle, so a cycle and the whole course cost different amounts, and estimates are usually per cycle.
Before travelling, ask how many cycles are planned, how the estimate changes if the regimen does, and whether some cycles can be given at home under the German centre’s supervision. Guide prices: chemotherapy cost in Germany.
Frequently asked questions
Can chemotherapy be prescribed remotely, from the documents?
A preliminary plan is possible, the final regimen is not. Reports, scans and slides show which treatment is likely, but doses depend on height, weight and fresh blood tests, and the patient is examined before the first cycle, so the regimen is confirmed in person.
How dangerous is chemotherapy?
It is serious treatment with real risks, above all infection when white cells are low: a temperature above 38 degrees needs urgent care. So blood is checked before every cycle, supportive drugs are planned ahead and patients learn when to call at once. Nobody can honestly promise no complications.
Can some cycles be given at home?
Sometimes, but only on the German centre’s written plan and by agreement with the treating doctor at home. The plan lists drugs, doses, intervals, tests before each cycle and results that mean postponing it; the local oncologist needs the same drugs, and the German centre reviews the results.
Can I have children after chemotherapy?
Often yes, but it cannot be predicted: the risk depends on drugs, doses and, in women, age, and is higher with alkylating agents and platinum drugs. So sperm, eggs or ovarian tissue can be frozen before the first cycle, and contraception is needed during treatment and for a while after.
How AlenMed arranges chemotherapy in Germany
We translate reports, scans and pathology findings, send slides for remote review to a centre treating this tumour, agree the first appointment, obtain the written estimate and arrange the visa invitation. An interpreter attends consultations and the discussion of the tumour board’s decision.
Between cycles the coordinator stays in touch and passes on home test results. The patient leaves with the written regimen with drug names and doses, the supportive-care plan and contacts for questions.
This material is for information only and is not an offer. A doctor decides the regimen and extent of treatment in person.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
